
Aeglea BioTherapeutics AGLE
Annual report 2025
added 02-19-2026
Aeglea BioTherapeutics P/S Ratio 2011-2026 | AGLE
Annual P/S Ratio Aeglea BioTherapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 489 | 0.579 | 0.667 | 19.2 K | - | 48.2 | 20 | 8.48 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 19.2 K | 0.579 | 2.83 K |
P/S Ratio of other stocks in the Biotechnology industry
| Issuer | P/S Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
1.75 | - | 2.43 % | $ 254 M | ||
|
Altimmune
ALT
|
7.76 K | $ 3.41 | 2.1 % | $ 300 M | ||
|
Amgen
AMGN
|
5.4 | $ 350.17 | 0.68 % | $ 188 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
1.73 | $ 19.57 | 0.36 % | $ 915 M | ||
|
I-Mab
IMAB
|
94.1 | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
5.53 | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
1.96 K | - | 2.54 % | $ 160 B | ||
|
Ascendis Pharma A/S
ASND
|
947 | $ 217.82 | -1.83 % | $ 5 B | ||
|
Autolus Therapeutics plc
AUTL
|
1.37 K | $ 1.4 | 1.82 % | $ 357 M | ||
|
Midatech Pharma plc
MTP
|
137 | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.39 K | - | -1.52 % | $ 24.7 M | ||
|
Aytu BioScience
AYTU
|
0.237 | $ 2.64 | 1.15 % | $ 16.6 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
65.5 | - | - | $ 26.5 M | ||
|
Aeterna Zentaris
AEZS
|
7.87 | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
0.099 | - | -10.17 % | $ 12.2 K | ||
|
Benitec Biopharma
BNTC
|
54.5 | $ 11.0 | 0.18 % | $ 453 M | ||
|
Acorda Therapeutics
ACOR
|
0.142 | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
13.3 | - | -0.23 % | $ 916 M | ||
|
Acasti Pharma
ACST
|
0.203 | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
2.61 | - | - | - | ||
|
Adverum Biotechnologies
ADVM
|
76.4 | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
25.8 | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
144 | - | -9.65 % | $ 45.9 M | ||
|
Coherus BioSciences
CHRS
|
5.36 | $ 1.58 | 3.62 % | $ 185 M | ||
|
Cellectis S.A.
CLLS
|
6.69 | $ 3.35 | 0.3 % | $ 116 M | ||
|
Ayala Pharmaceuticals
AYLA
|
11.2 | - | - | $ 7.46 M | ||
|
Cullinan Management
CGEM
|
35.1 | $ 12.83 | 0.71 % | $ 773 M | ||
|
BioDelivery Sciences International
BDSI
|
1.85 | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
66.4 | - | 0.49 % | $ 251 B | ||
|
Calithera Biosciences
CALA
|
98.5 | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
2.58 | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
0.0564 | - | - | $ 3.74 B | ||
|
CorMedix
CRMD
|
0.00146 | $ 6.29 | 0.64 % | $ 453 K | ||
|
CytomX Therapeutics
CTMX
|
12.2 | $ 4.41 | -1.01 % | $ 608 M | ||
|
Checkpoint Therapeutics
CKPT
|
3.91 K | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
1.55 | - | -7.23 % | $ 13 M | ||
|
CureVac N.V.
CVAC
|
281 | - | - | $ 867 M | ||
|
Compugen Ltd.
CGEN
|
49.8 | $ 2.12 | 1.2 % | $ 198 M | ||
|
Denali Therapeutics
DNLI
|
7.68 | $ 20.92 | 3.69 % | $ 3.44 B | ||
|
Dyadic International
DYAI
|
16.6 | $ 0.89 | -5.85 % | $ 25.6 M | ||
|
Arbutus Biopharma Corporation
ABUS
|
24.5 | $ 4.26 | 0.47 % | $ 707 M |